Mechanotransduction and Stiffness-Sensing: Mechanisms and Opportunities to Control Multiple Molecular Aspects of Cell Phenotype as a Design Cornerstone of Cell-Instructive Biomaterials for Articular Cartilage Repair

Int J Mol Sci. 2020 Jul 29;21(15):5399. doi: 10.3390/ijms21155399.

Abstract

Since material stiffness controls many cell functions, we reviewed the currently available knowledge on stiffness sensing and elucidated what is known in the context of clinical and experimental articular cartilage (AC) repair. Remarkably, no stiffness information on the various biomaterials for clinical AC repair was accessible. Using mRNA expression profiles and morphology as surrogate markers of stiffness-related effects, we deduced that the various clinically available biomaterials control chondrocyte (CH) phenotype well, but not to equal extents, and only in non-degenerative settings. Ample evidence demonstrates that multiple molecular aspects of CH and mesenchymal stromal cell (MSC) phenotype are susceptible to material stiffness, because proliferation, migration, lineage determination, shape, cytoskeletal properties, expression profiles, cell surface receptor composition, integrin subunit expression, and nuclear shape and composition of CHs and/or MSCs are stiffness-regulated. Moreover, material stiffness modulates MSC immuno-modulatory and angiogenic properties, transforming growth factor beta 1 (TGF-β1)-induced lineage determination, and CH re-differentiation/de-differentiation, collagen type II fragment production, and TGF-β1- and interleukin 1 beta (IL-1β)-induced changes in cell stiffness and traction force. We then integrated the available molecular signaling data into a stiffness-regulated CH phenotype model. Overall, we recommend using material stiffness for controlling cell phenotype, as this would be a promising design cornerstone for novel future-oriented, cell-instructive biomaterials for clinical high-quality AC repair tissue.

Keywords: Rho-GTPases; RhoA/Rho associated protein kinase (ROCK); SRY-related HMG box gene 9 (SOX9); TGF-β; Wnt; articular cartilage; biomaterials; cartilage repair; cell shape; chondrocyte; clinical; de-differentiation; immunomodulation; mechanotransduction; mesenchymal stromal cells (MSCs); osteoarthritis; phenotype modulation; re-differentiation; stiffness sensing; α-catenin; β-catenin.

Publication types

  • Review

MeSH terms

  • Biocompatible Materials / chemistry*
  • Biocompatible Materials / therapeutic use
  • Biomarkers / metabolism
  • Cartilage, Articular / drug effects*
  • Cartilage, Articular / immunology
  • Cartilage, Articular / pathology
  • Cartilage, Articular / surgery
  • Cell Differentiation / drug effects
  • Cell Proliferation / drug effects
  • Chondrocytes / cytology
  • Chondrocytes / drug effects*
  • Chondrocytes / metabolism
  • Chondrogenesis / drug effects
  • Chondrogenesis / genetics
  • Collagen Type II / genetics
  • Collagen Type II / metabolism
  • Gene Expression Regulation
  • Hardness / physiology
  • Humans
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Mechanotransduction, Cellular / genetics*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / metabolism
  • Osteoarthritis / genetics
  • Osteoarthritis / immunology
  • Osteoarthritis / surgery
  • Osteoarthritis / therapy*
  • Phenotype
  • Regeneration / drug effects*
  • Regeneration / genetics
  • SOX9 Transcription Factor / genetics
  • SOX9 Transcription Factor / metabolism
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism
  • beta Catenin / genetics
  • beta Catenin / metabolism

Substances

  • Biocompatible Materials
  • Biomarkers
  • CTNNB1 protein, human
  • Collagen Type II
  • IL1B protein, human
  • Interleukin-1beta
  • SOX9 Transcription Factor
  • SOX9 protein, human
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • beta Catenin